Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis

Stroke

Volumn 36, Issue 10, 2005, Pages 2286-2288

  Abou Chebl, Alex ^a   Bajzer, Christopher T ^a   Krieger, Derk W ^a   Furlan, Anthony J ^a   Yadav, Jay S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute; Angioplasty; Endovascular therapy; Platelet aggregation inhibitors; Stroke; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BASILAR ARTERY; BLEEDING; BLOOD CLOT LYSIS; BOLUS INJECTION; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DEVICE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EMBOLECTOMY; HOSPITAL DISCHARGE; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROANATOMY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PETECHIA; PRIORITY JOURNAL; RECANALIZATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; STENT; SUBARACHNOID HEMORRHAGE; SYMPTOMATOLOGY; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANGIOPLASTY; BRAIN ISCHEMIA; CAROTID STENOSIS; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; COMBINED MODALITY THERAPY; EMBOLECTOMY; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; STENTS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 26444600193     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000179043.73314.4f     Document Type: Article

References (8)

1. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
2. Doggrell SA. Alteplase: descendancy in myocardial infarction, ascendancy in stroke. Exp Opin Investig Drugs. 2001;10:2013-2029.
3. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438-441.
4. Lee DH, Jo KD, Kim HG, Choi SJ, Jung SM, Ryu DS, Park MS. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol. 2002;13:769-774.
5. Nakano S, Iseda T, Yoneyama T, Kawano H, Wakisaka S. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis. Stroke. 2002;33:2872-2876.
6. Chopko BW, Kerber C, Wong W, Grorgy B. Transcatheter snare removal of acute middle cerebral artery thromboembolism: technical case report. Neurosurgery. 2000;46:1529-1531.
7. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. The Abciximab in Ischemic Stroke Investigators. Stroke. 2005;36:880-890.
8. Levy DE, Brott TG, Haley EC Jr, Marler JR, Sheppard GL, Barsan W, Broderick JP. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994;25:291-297.